Insmed price target raised to $72 from $55 at JPMorgan

JPMorgan raised the firm’s price target on Insmed to $72 from $55 and keeps an Overweight rating on the shares. Following recent calls with key opinion leaders who gave “highly enthusiastic feedback” on the potential uptake for brensocatib in non-cystic fibrosis bronchiectasis, or NCFBE, the firm is raising its estimates and now models 2035 worldwide sales of about $5B in NCFBE, the analyst tells investors.